For Research Use Only

Lamin B2 Polyclonal antibody

Catalog Number:10895-1-AP

Featured Product

21 Publications




Basic Information	Catalog Number: 10895-1-AP	GenBank Accession BC006551	n Number:	Purification Method: Antigen affinity purification	
	Size: 150ul, Concentration: 1000 µg/ml by Nanodrop and 400 µg/ml by Bradforc method using BSA as the standard;	Full Name:		Recommended Dilutions: WB 1:2000-1:10000 IP 0.5-4.0 ug for IP and 1:500-1:1000 for WB	
	Source: Rabbit	lamin B2 Calculated MW: 68 kDa		IHC 1:50-1:500 IF 1:50-1:500	
	lsotype: IgG	Observed MW: 66-68 kDa			
	Immunogen Catalog Number: AG1335				
Applications	Tested Applications: FC, IF, IHC, IP, WB, ELISA	Positive Con			
	Cited Applications:	ications: tissue		cells, Jurkat cells, Raji cells, mouse brai	
	IF, IHC, WB			ls,	
	Species Specificity: human, mouse, rat			ung cancer tissue, human colon cancer	
	Cited Species: human, rat, mouse			lls, SH-SY5Y cells	
	Note-IHC: suggested antigen ı TE buffer pH 9.0; (*) Alternati retrieval may be performed w buffer pH 6.0	vely, antigen			
Background Information	Lamins are nuclear membrane structural components that are important in structural integrity of the nucleus and may also interact with chromatin (PMID: 33033404). Research studies show that lamin B2 knockout mice exhibit neuronal developmental defects and that both proteins are essential for typical brain development (PMID: 20145110). Mutations in Lamin B2 can result in a susceptibility to developing acquired partial lipodystrophy, a ran disorder characterized by the progressive loss of subcutaneous fat in a bilaterally symmetrical fashion (PMID: 16826530).				
	20145110). Mutations in Lamin B2 ca disorder characterized by the progres	n result in a suscept		ng acquired partial lipodystrophy, a ra	
	20145110). Mutations in Lamin B2 ca disorder characterized by the progres 16826530).	n result in a suscept ssive loss of subcuta		ng acquired partial lipodystrophy, a rai	
	20145110). Mutations in Lamin B2 ca disorder characterized by the progres 16826530). Author Pu	n result in a suscept ssive loss of subcuta	neous fat in a bila	ng acquired partial lipodystrophy, a rai terally symmetrical fashion (PMID:	
	20145110). Mutations in Lamin B2 ca disorder characterized by the progres 16826530). Author Pu Ralf Willebrand 30	n result in a suscept ssive loss of subcuta bomed ID Jo 183074 Eu	neous fat in a bilar purnal	ng acquired partial lipodystrophy, a ra terally symmetrical fashion (PMID: Application	
	20145110). Mutations in Lamin B2 ca disorder characterized by the progress 16826530).AuthorPu Ralf WillebrandRalf Willebrand30Huanhuan Sha36	n result in a suscept ssive loss of subcuta bmed ID Jo 1183074 Eu 5266920 Ca	neous fat in a bilat ournal ur J Immunol	ng acquired partial lipodystrophy, a ra terally symmetrical fashion (PMID: Application WB	
Notable Publications	20145110). Mutations in Lamin B2 ca disorder characterized by the progress 16826530). Author Pu Ralf Willebrand 30 Huanhuan Sha 36	n result in a suscept ssive loss of subcuta bmed ID Jo 1183074 Eu 5266920 Ca 5721038 Fr ter shipment.	neous fat in a bilar ournal ur J Immunol ancer Med	ng acquired partial lipodystrophy, a ra terally symmetrical fashion (PMID: Application WB WB	
Notable Publications	20145110). Mutations in Lamin B2 ca disorder characterized by the progress 16826530). Author Pu Ralf Willebrand 30 Huanhuan Sha 36 Ziying Wei 34 Storage: Storage Buffer:	n result in a suscept ssive loss of subcuta bened ID Jo 1183074 Eu 5266920 Ca 5721038 Fr ter shipment.	neous fat in a bilar ournal ur J Immunol ancer Med	ng acquired partial lipodystrophy, a ra terally symmetrical fashion (PMID: Application WB WB	


For technical support and original validation data for this product please contact:T: 1 (888) 4PTGLAB (1-888-478-4522) (toll freeE: proteintech@ptglab.comin USA), or 1(312) 455-8498 (outside USA)W: ptglab.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.

Selected Validation Data




Various lysates were subjected to SDS PAGE followed by western blot with 10895-1-AP (LMNB2 antibody) at dilution of 1:8000 incubated at room temperature for 1.5 hours.




Immunohistochemical analysis of paraffinembedded human colon cancer tissue slide using 10895-1-AP (LMNB2 antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).




Immunofluorescent analysis of (-20°C Ethanol) fixed HepG2 cells using 10895-1-AP (LMNB2 antibody) at dilution of 1:100 and Alexa Fluor 488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).



Immunohistochemical analysis of paraffinembedded human lung cancer tissue slide using 10895-1-AP (LMNB2 antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



IP Result of anti-LMNB2 (IP:10895-1-AP, 3ug; Detection:10895-1-AP 1:500) with Jurkat cells lysate 2400ug.



1X10^6 HEK-293T cells were stained with 0.2ug LMNB2 antibody (10895-1-AP, red) and control antibody (blue). Fixed with 90% MeOH blocked with 3% BSA (30 min). Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) with dilution 1:1000.